Algert Global LLC Buys 31,250 Shares of Mirum Pharmaceuticals, Inc. $MIRM

Algert Global LLC raised its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 19.6% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 190,599 shares of the company’s stock after buying an additional 31,250 shares during the quarter. Algert Global LLC owned about 0.37% of Mirum Pharmaceuticals worth $13,973,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of MIRM. Comerica Bank boosted its position in shares of Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares during the period. AQR Capital Management LLC lifted its stake in Mirum Pharmaceuticals by 307.3% in the 1st quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock worth $2,211,000 after purchasing an additional 37,028 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Mirum Pharmaceuticals by 7.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock worth $1,176,000 after purchasing an additional 1,720 shares in the last quarter. Caxton Associates LLP bought a new position in Mirum Pharmaceuticals in the 1st quarter valued at $217,000. Finally, Empowered Funds LLC grew its position in shares of Mirum Pharmaceuticals by 15.4% during the 1st quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock valued at $1,729,000 after purchasing an additional 5,120 shares in the last quarter.

Mirum Pharmaceuticals Stock Up 1.0%

MIRM opened at $90.66 on Monday. The stock has a market cap of $5.47 billion, a PE ratio of -188.87 and a beta of 0.52. The company has a quick ratio of 2.55, a current ratio of 2.67 and a debt-to-equity ratio of 0.98. Mirum Pharmaceuticals, Inc. has a 52 week low of $36.88 and a 52 week high of $109.28. The business’s fifty day simple moving average is $95.39 and its 200 day simple moving average is $80.72.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.53%. The firm had revenue of $148.93 million for the quarter, compared to analysts’ expectations of $141.78 million. During the same quarter in the previous year, the business earned $1.00 EPS. The company’s revenue for the quarter was up 49.8% on a year-over-year basis. As a group, research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, Director Patrick J. Heron purchased 131,425 shares of the firm’s stock in a transaction on Friday, January 23rd. The shares were purchased at an average cost of $68.48 per share, with a total value of $8,999,984.00. Following the completion of the purchase, the director owned 459,010 shares of the company’s stock, valued at $31,433,004.80. The trade was a 40.12% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Jolanda Howe sold 968 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $103.30, for a total transaction of $99,994.40. Following the transaction, the senior vice president directly owned 4,503 shares in the company, valued at approximately $465,159.90. This represents a 17.69% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 45,136 shares of company stock worth $4,352,029 over the last ninety days. Corporate insiders own 22.87% of the company’s stock.

Analysts Set New Price Targets

MIRM has been the topic of a number of recent analyst reports. Raymond James Financial reiterated a “strong-buy” rating and issued a $110.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, December 11th. Leerink Partners reduced their target price on Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating for the company in a research report on Thursday, February 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research note on Thursday, January 22nd. Evercore set a $126.00 price target on Mirum Pharmaceuticals in a research report on Wednesday, March 4th. Finally, Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Friday, December 19th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Mirum Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $117.00.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.